vs
ProFrac Holding Corp.（ACDC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是ProFrac Holding Corp.的1.4倍（$622.0M vs $436.5M），Royalty Pharma plc净利率更高（34.4% vs -33.2%，领先67.6%），Royalty Pharma plc同比增速更快（4.8% vs -4.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -13.4%）
ProFrac Holding Corp.是一家领先的北美能源服务企业，主要为油气勘探开采企业提供水力压裂、完井及相关配套服务，核心客户覆盖美国、加拿大主要陆上页岩及常规油气产区的上游运营商。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ACDC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.4倍
$436.5M
营收增速更快
RPRX
高出8.8%
-4.0%
净利率更高
RPRX
高出67.6%
-33.2%
两年增速更快
RPRX
近两年复合增速
-13.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $436.5M | $622.0M |
| 净利润 | $-144.7M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | -24.9% | 62.4% |
| 净利率 | -33.2% | 34.4% |
| 营收同比 | -4.0% | 4.8% |
| 净利润同比 | -37.8% | 2.9% |
| 每股收益（稀释后） | $-0.83 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACDCRPRX
| Q4 25 | $436.5M | $622.0M | ||
| Q3 25 | $403.1M | $609.3M | ||
| Q2 25 | $501.9M | $578.7M | ||
| Q1 25 | $600.3M | $568.2M | ||
| Q4 24 | $454.7M | $593.6M | ||
| Q3 24 | $575.3M | $564.7M | ||
| Q2 24 | $579.4M | $537.3M | ||
| Q1 24 | $581.5M | $568.0M |
净利润ACDCRPRX
| Q4 25 | $-144.7M | $214.2M | ||
| Q3 25 | $-100.9M | $288.2M | ||
| Q2 25 | $-105.9M | $30.2M | ||
| Q1 25 | $-17.5M | $238.3M | ||
| Q4 24 | $-105.0M | $208.2M | ||
| Q3 24 | $-45.2M | $544.0M | ||
| Q2 24 | $-66.7M | $102.0M | ||
| Q1 24 | $1.8M | $4.8M |
营业利润率ACDCRPRX
| Q4 25 | -24.9% | 62.4% | ||
| Q3 25 | -19.5% | 70.1% | ||
| Q2 25 | -10.8% | 36.3% | ||
| Q1 25 | 2.7% | 94.0% | ||
| Q4 24 | -10.3% | 60.9% | ||
| Q3 24 | -0.7% | — | ||
| Q2 24 | -8.5% | 50.2% | ||
| Q1 24 | 6.9% | -13.0% |
净利率ACDCRPRX
| Q4 25 | -33.2% | 34.4% | ||
| Q3 25 | -25.0% | 47.3% | ||
| Q2 25 | -21.1% | 5.2% | ||
| Q1 25 | -2.9% | 41.9% | ||
| Q4 24 | -23.1% | 35.1% | ||
| Q3 24 | -7.9% | 96.3% | ||
| Q2 24 | -11.5% | 19.0% | ||
| Q1 24 | 0.3% | 0.8% |
每股收益（稀释后）ACDCRPRX
| Q4 25 | $-0.83 | $0.49 | ||
| Q3 25 | $-0.60 | $0.67 | ||
| Q2 25 | $-0.67 | $0.07 | ||
| Q1 25 | $-0.12 | $0.55 | ||
| Q4 24 | $-0.67 | $0.46 | ||
| Q3 24 | $-0.29 | $1.21 | ||
| Q2 24 | $-0.42 | $0.23 | ||
| Q1 24 | $0.00 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.9M | $618.7M |
| 总债务越低越好 | $832.7M | $9.0B |
| 股东权益账面价值 | $717.5M | $9.7B |
| 总资产 | $2.6B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.16× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ACDCRPRX
| Q4 25 | $22.9M | $618.7M | ||
| Q3 25 | $58.0M | $938.9M | ||
| Q2 25 | $26.0M | $631.9M | ||
| Q1 25 | $16.0M | $1.1B | ||
| Q4 24 | $14.8M | $929.0M | ||
| Q3 24 | $25.5M | $950.1M | ||
| Q2 24 | $24.0M | $1.8B | ||
| Q1 24 | $28.3M | $843.0M |
总债务ACDCRPRX
| Q4 25 | $832.7M | $9.0B | ||
| Q3 25 | $907.0M | $8.9B | ||
| Q2 25 | $941.9M | $8.0B | ||
| Q1 25 | $967.9M | $7.6B | ||
| Q4 24 | $936.1M | $7.6B | ||
| Q3 24 | $986.7M | $7.6B | ||
| Q2 24 | $1.0B | $7.6B | ||
| Q1 24 | $895.1M | $6.1B |
股东权益ACDCRPRX
| Q4 25 | $717.5M | $9.7B | ||
| Q3 25 | $862.0M | $9.6B | ||
| Q2 25 | $875.5M | $9.5B | ||
| Q1 25 | $988.1M | $9.8B | ||
| Q4 24 | $1.0B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.1B | $9.8B | ||
| Q1 24 | $1.2B | $9.9B |
总资产ACDCRPRX
| Q4 25 | $2.6B | $19.6B | ||
| Q3 25 | $2.7B | $19.3B | ||
| Q2 25 | $2.8B | $18.3B | ||
| Q1 25 | $3.0B | $17.6B | ||
| Q4 24 | $3.0B | $18.2B | ||
| Q3 24 | $3.1B | $18.0B | ||
| Q2 24 | $3.2B | $17.7B | ||
| Q1 24 | $3.0B | $16.1B |
负债/权益比ACDCRPRX
| Q4 25 | 1.16× | 0.92× | ||
| Q3 25 | 1.05× | 0.93× | ||
| Q2 25 | 1.08× | 0.84× | ||
| Q1 25 | 0.98× | 0.78× | ||
| Q4 24 | 0.93× | 0.74× | ||
| Q3 24 | 0.90× | 0.74× | ||
| Q2 24 | 0.88× | 0.78× | ||
| Q1 24 | 0.74× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $12.9M | — |
| 自由现金流率自由现金流/营收 | 3.0% | — |
| 资本支出强度资本支出/营收 | 8.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $19.6M | — |
8季度趋势，按日历期对齐
经营现金流ACDCRPRX
| Q4 25 | $49.5M | $827.1M | ||
| Q3 25 | $900.0K | $702.6M | ||
| Q2 25 | $100.4M | $364.0M | ||
| Q1 25 | $38.7M | $596.1M | ||
| Q4 24 | $76.5M | $742.5M | ||
| Q3 24 | $98.2M | $703.6M | ||
| Q2 24 | $113.5M | $658.2M | ||
| Q1 24 | $79.1M | $664.6M |
自由现金流ACDCRPRX
| Q4 25 | $12.9M | — | ||
| Q3 25 | $-33.4M | — | ||
| Q2 25 | $53.9M | — | ||
| Q1 25 | $-13.8M | — | ||
| Q4 24 | $13.3M | — | ||
| Q3 24 | $28.2M | — | ||
| Q2 24 | $51.6M | — | ||
| Q1 24 | $19.2M | — |
自由现金流率ACDCRPRX
| Q4 25 | 3.0% | — | ||
| Q3 25 | -8.3% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | 3.3% | — |
资本支出强度ACDCRPRX
| Q4 25 | 8.4% | — | ||
| Q3 25 | 8.5% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 12.2% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 10.3% | — |
现金转化率ACDCRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 43.94× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACDC
| Services | $385.6M | 88% |
| Products | $50.9M | 12% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
